SEL-212 for Chronic Severe Gout

view our pipeline

SEL-212 is being developed as a monthly treatment consisting of pegsiticase, a potent uric acid lowering uricase enzyme, co-administered with SVP-Rapamycin to prevent anti-drug antibodies (ADAs). Selecta has generated clinical data indicating that this product candidate has an ability to drastically and durably lower serum uric acid to levels conducive to rapid tophi dissolution and the reduction of flares and other symptoms.
 

For More Information

Please visit the following resources and organizations for additional information about gout:

American College of Rheumatology
Arthritis Foundation
National Data Bank for Rheumatic Diseases
National Institute of Arthritis and Muscoskeletal and Skin Diseases
National Institutes of Health
National Library of Medicine
The Gout & Uric Acid Education Society
U.S. Food & Drug Administration

Back to Top